Noch Fragen? 0800 / 33 82 637

Handbook of HER2-targeted agents in breast cancer

Produktform: E-Buch Text Elektronisches Buch in proprietärem

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.weiterlesen

Elektronisches Format: PDF

Sprache(n): Englisch

ISBN: 978-1-907673-94-8 / 978-1907673948 / 9781907673948

Verlag: Springer Healthcare

Erscheinungsdatum: 28.05.2014

Seiten: 96

Autor(en): Nadia Harbeck, Martine Piccart, Ricardo H Alvarez, Javier Cortés, Leticia Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni, Stefania Zambelli, Dimitrios Zardavas

42,79 € inkl. MwSt.
Recommended Retail Price
kostenloser Versand

lieferbar - Lieferzeit 10-15 Werktage

zurück